Philippe Chemla, MBA, Ph.D.
Chief Executive Officer
Dr. Philippe Chemla leads business development, including commercial partnerships and company financing. Prior to joining Clinical Sensors, Philippe served as Vice President of Business Development at Metabolon where he established strategic partnerships with industry segment leaders. Philippe also held leadership positions at Fujifilm Diosynth Biotechnology, Ciba, Novartis and Syngenta.
Mark Schoenfisch, Ph.D.
Founder and President
Dr. Mark Schoenfisch is Professor of Chemistry at UNC-Chapel Hill. He is an expert in electrochemical sensors, nitric oxide (NO), and bio-functional membranes. Dr. Schoenfisch has a long-standing interest in understanding nitric oxide’s role in physiology and has developed a dynamic research program focused on harnessing NO. He has published over 100 papers on NO measurement, storage, and controlled release. Clinical Sensors, Inc. is Dr. Schoenfisch's second biotechnology venture after Novan Therapeutics, a clinical stage company focused on NO-based therapeutics.
Jon McDunn, Ph.D.
Head of Research and Development
Dr. Jon McDunn leads engineering, preclinical, and clinical projects and has over 20-years experience in clinical research and the launch of medical devices and research services. He is an expert in the biology of inflammation, and has worked to understand physiologic changes that occur during the onset of inflammatory and infectious disease. He led product development and commercialization teams at Incyte Genomics and Metabolon before joining Clinical Sensors. Dr. McDunn has 50 published paper, 2 issued patents, and is an adjunct faculty member in Biomedical Engineering at UNC-Chapel Hill.
Wesley Storm, Ph.D.
Dr. Wesley Storm leads electrochemical method development, sensor and membrane design, and standardization efforts. Dr. Storm studied under Dr. Schoenfisch, and has seven years experience in areas spanning nitric oxide chemistry, membrane synthesis, membrane deposition electrochemistry, and biological assays. Dr. Storm has won over $1.5 million of non-dilutive NIH Phase I and II SBIR grants for Clinical Sensors.